APA (7th ed.) Citation

Li, V., McKay, F. C., Tscharke, D. C., Smith, C., Khanna, R., Lechner-Scott, J., . . . Frost, B. (2025). Repurposing Licensed Drugs with Activity Against Epstein–Barr Virus for Treatment of Multiple Sclerosis: A Systematic Approach: Anti-EBV Drugs for MS: V. Li et al. CNS Drugs, 39(3), 305. https://doi.org/10.1007/s40263-024-01153-5

Chicago Style (17th ed.) Citation

Li, Vivien, et al. "Repurposing Licensed Drugs with Activity Against Epstein–Barr Virus for Treatment of Multiple Sclerosis: A Systematic Approach: Anti-EBV Drugs for MS: V. Li Et Al." CNS Drugs 39, no. 3 (2025): 305. https://doi.org/10.1007/s40263-024-01153-5.

MLA (9th ed.) Citation

Li, Vivien, et al. "Repurposing Licensed Drugs with Activity Against Epstein–Barr Virus for Treatment of Multiple Sclerosis: A Systematic Approach: Anti-EBV Drugs for MS: V. Li Et Al." CNS Drugs, vol. 39, no. 3, 2025, p. 305, https://doi.org/10.1007/s40263-024-01153-5.